Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$5.85 USD
+0.44 (8.13%)
Updated Sep 22, 2025 03:59 PM ET
After-Market: $5.86 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KPTI 5.85 +0.44(8.13%)
Will KPTI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Other News for KPTI
New Downtrend appears for KPTI after 5.58% move
Is KPTI gaining bullish strength? Non-ADX 1,2,3,4 Bullish shows up after tumbling 5.76%
KPTI's price falls by 2.88% on September 17, though its technical setup remains stable.
KPTI forms NR7 on September 16
KPTI forms 20 Day Moving Average Resistance on September 15